Published in final edited form as:

J Matern Fetal Neonatal Med. 2009 December ; 22(12): 1151–1166. doi:10.3109/14767050903019684.

Amniotic Fluid Soluble HLA-G in Term and Preterm Parturition, and Intra-amniotic Infection/Inflammation

Juan Pedro Kusanovic^{1,2}, Roberto Romero^{1,2,3}, Cristiano Jodicke^{1,2}, Shali Mazaki-Tovi^{1,2}, Edi Vaisbuch^{1,2}, Offer Erez^{1,2}, Pooja Mittal^{1,2}, Francesca Gotsch¹, Tinnakorn Chaiworapongsa^{1,2}, Sam S. Edwin¹, Percy Pacora¹, and Sonia S. Hassan^{1,2}

¹Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland and Detroit, Michigan, USA

²Wayne State University School of Medicine, Department of Obstetrics and Gynecology, Detroit, Michigan, USA

³Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA

Abstract

Objective—Circulating soluble HLA-G (sHLA-G) has been associated with pregnancy complications, and determination of sHLA-G concentrations in amniotic fluid (AF) has been reported in normal pregnancies. Our aim was to determine if the AF concentrations of sHLA-G change with advancing gestation, spontaneous labor at term, and in patients with spontaneous preterm labor (PTL) with intact membranes, as well as in those with preterm prelabor rupture of membranes (PROM), in the presence or absence of intraamniotic infection/inflammation (IAI).

Study design—This cross-sectional study included the following groups: 1) midtrimester (n=55); 2) normal pregnancy at term with (n=50) and without (n=50) labor; 3) spontaneous PTL with intact membranes divided into: a) PTL who delivered at term (n=153); b) PTL who delivered preterm without IAI (n=108); and c) PTL with IAI (n=84); and 4) preterm PROM with (n=46) and without (n=44) IAI. sHLA-G concentrations were determined by ELISA. Non-parametric statistics were used for analysis.

Results—1) Among patients with PTL, the median AF sHLA-G concentration was higher in patients with IAI than in those without IAI or women that delivered at term ($p<0.001$ for both comparisons); 2) Similarly, patients with preterm PROM and IAI had higher median AF sHLA-G concentrations than those without IAI ($p=0.004$); 3) Among patients with PTL and delivery, those with histologic chorioamnionitis and/or funisitis had a higher median AF sHLA-G concentration than those without histologic inflammation ($p<0.001$); and 4) The median AF sHLA-G concentration did not change with advancing gestational age.

Conclusions—AF sHLA-G concentrations are elevated in preterm parturition associated to IAI as well as in histologic chorioamnionitis. We propose that sHLA-G may participate in the regulation of the host immune response against intra-amniotic infection.

Keywords

sHLA-G; preterm labor; preterm delivery; preterm prelabor rupture of membranes; pregnancy; amniocentesis; microbial invasion of the amniotic cavity; chorioamnionitis

INTRODUCTION

Spontaneous preterm labor (PTL) with intact membranes and preterm prelabor rupture of membranes (PROM) are syndromes caused by multiple etiologies that can activate the common terminal pathway of parturition,[1] and intrauterine infection is one of the most important mechanisms of disease causally linked to preterm birth.[2–12] Intraamniotic infection and/or inflammation (IAI) is present in approximately one third of patients with spontaneous preterm labor[13] and in almost half of patients with preterm PROM,[14] it is associated with development of fetal inflammatory response syndrome,[15,16] and is considered an important risk factor for development of fetal injury.[17–30] Other pathological processes implicated in the preterm parturition syndrome include cervical insufficiency,[31,32] uterine overdistension,[33] allergy,[34–37] endocrine disorders,[38–41] vascular insults,[42–45] and abnormal allograft reaction.[46] It has been suggested that abnormalities in the recognition and adaptation to a set of foreign antigens, such as fetal antigens, may be a mechanism of disease responsible for intrauterine growth restriction, preeclampsia and recurrent pregnancy loss.[47–49]

HLA-G is a molecule that belongs to the class I region of the major histocompatibility complex, which includes the HLA class Ia genes that encode the classical high polymorphic transplantation antigens (HLA-A, -B, -C), and the nonclassical class Ib genes (HLA-E, -F, and -G).[50] HLA-G is called “nonclassic” because it also differs from classic HLA class Ia molecules by its genetic diversity, expression, structure, and functions.[51] HLA-G is characterized by an expression pattern of seven isoforms: four membrane-bound isoforms (HLA-G1, G2, G3 and G4) and three soluble isoforms (HLA-G5, G6 and G7)[52–55] that are generated by alternative splicing of a unique primary transcript.[56–58] HLA-A, -B and -C show broad tissue expression, whereas HLA-G expression is highly tissue-restricted, placenta being one of the most important organs for HLA-G expression.[59–63]

Soluble HLA-G (sHLA-G) isoforms were found to function as immuno-tolerant molecules by inhibiting NK cells function,[64] and a solid body of evidence supports a role for sHLA-G concentrations in maternal blood in the pathophysiology of recurrent spontaneous abortion, preeclampsia, intrauterine growth restriction, placental abruption, spontaneous preterm labor and preterm PROM.[65–69] Of interest, increased expression of HLA-G has been reported in infectious and autoimmune/inflammatory diseases,[70] as well as in patients with septic shock.[71] In pregnancy, sHLA-G has been detected in amniotic fluid of normal pregnant women in the second and third trimesters.[72–76] The objective of this study was to determine if the amniotic fluid concentrations of sHLA-G change with advancing gestation, spontaneous labor at term, and in patients with spontaneous PTL as well as in those with preterm PROM, in the presence or absence of intra-amniotic infection/inflammation.

MATERIALS AND METHODS

Study design and population

A cross-sectional study was designed by searching our clinical database and bank of biological samples including 590 patients in the following groups: 1) women in the mid-trimester of pregnancy (14–18 weeks) who underwent amniocentesis for genetic indications and delivered a normal neonate at term (n=55); 2) normal pregnant women at term with (n=50) and without (n=50) spontaneous labor; 3) patients with an episode of spontaneous preterm labor (PTL) and intact membranes who were classified into: a) PTL without IAI who delivered at term (n=153); b) PTL without IAI who delivered preterm (<37 weeks gestation) (n=108); and c) PTL with IAI (n=84); and 4) women with preterm PROM with (n=46) and without (n=44) IAI. Information regarding the racial composition of patients

included in this study was available in 91% (534/590) of cases, and included: 66% (389/590) Hispanic, 22% African-American (130/590), and 2.5% (15/590) Caucasian.

All women provided written informed consent prior to the collection of amniotic fluid. The collection of amniotic fluid and its utilization for research purposes was approved by the Institutional Review Boards of participating institutions and by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, NIH, DHHS. Many of these samples have been previously used to study the biology of inflammation, hemostasis, and growth factor concentrations in normal pregnant women and those with pregnancy complications.

Definitions

The definitions of normal pregnancy, spontaneous preterm labor and preterm PROM have been previously described.[77] Intra-amniotic infection was defined as a positive amniotic fluid culture for microorganisms. Intra-amniotic inflammation was diagnosed by an amniotic fluid interleukin (IL)-6 concentration ≥ 2.6 ng/mL.[13] Histologic chorioamnionitis was diagnosed based on the infiltration by neutrophils of the chorionic plate or of the extraplacental membranes. Acute funisitis was diagnosed by the presence of neutrophils in the wall of the umbilical vessels and/or Wharton's jelly using the criteria previously described.[78]

Amniotic fluid collection

Collection and processing of amniotic fluid samples have been described elsewhere.[77] White blood cell (WBC) count, glucose concentration and Gram stain were performed shortly after collection.[79–81] The results of these tests were used for clinical management, while amniotic fluid IL-6 concentrations were used only for research purposes. Among patients with spontaneous preterm labor with intact membranes who delivered within 72 hours of amniocentesis, placenta, umbilical cord, and chorioamniotic membranes were collected and the presence or absence of histologic chorioamnionitis and/or funisitis was assessed. This period of time was selected to preserve a meaningful temporal relationship between amniotic fluid sHLA-G concentration and placental pathologic findings.

Soluble Human Leukocyte Antigen G immunoassay

Specific and sensitive enzyme-linked immunoassay was utilized to determine concentrations of sHLA-G in human amniotic fluid. This immunoassay reacts with the soluble HLA-G5 isoform. Soluble HLA-G immunoassays were obtained from BioVendor, LLC (Chandler, NC, USA) and EXBIO Praha (Vestec, Czech Republic) were specifically validated in our laboratory for human amniotic fluid prior to the conduction of this study. The calculated inter- and intra-assay coefficients of variation for sHLA-G immunoassays in our laboratory were 7.2% and 4.2%. The sensitivity was calculated to be 1.67 U/ml.

Statistical analysis

The Shapiro-Wilk and Kolmogorov-Smirnov tests were used to test for normal distribution of the data. Since amniotic fluid sHLA-G concentrations were not normally distributed, non-parametric tests were used for analyses. Comparisons between proportions were performed with Chi-square test. The Kruskal-Wallis with post-hoc Mann-Whitney U test was used for comparisons of continuous variables. Adjustment for multiple comparisons was performed using the Bonferroni method.[82] Spearman rank correlation was utilized to assess correlations between amniotic fluid concentration of sHLA-G, glucose, IL-6 and WBC count. A p-value of <0.05 was considered statistically significant. The statistical package used was SPSS v.15.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Demographic and clinical characteristics of the study population

Table I shows the demographic and clinical characteristics of patients in the midtrimester, term no labor and term in labor groups. Tables II and III display the demographic and clinical characteristics of patients with spontaneous preterm labor and intact membranes and those with preterm PROM, respectively. The median gestational age at amniocentesis was significantly lower in patients with spontaneous preterm labor with intact membranes with IAI than in those without IAI who deliver preterm, and than that of those who deliver at term (Table II). Similar results were observed between patients with preterm PROM with IAI when compared to those without IAI (Table III).

Amniotic fluid sHLA-G in normal pregnancy and term parturition

Soluble HLA-G was detected in 99.7% (588/590) of amniotic fluid samples. There were no significant differences in the median sHLA-G concentration in amniotic fluid between women in the mid-trimester and that of those with a normal pregnancy at term not in labor [60.7 U/mL vs. 47.6 U/mL, respectively; $p=0.5$] (Figure 1). Patients with spontaneous labor at term had a significantly lower median amniotic fluid sHLA-G concentration than those without labor (36.2 U/mL vs. 47.6 U/mL, respectively; $p=0.02$) (Figure 2).

Information of fetal gender was available in 488 cases. No differences were found in the median amniotic fluid concentration of sHLA-G between male and female fetuses (57.3 U/mL vs. 50.7 U/mL, respectively; $p=0.8$).

Amniotic fluid sHLA-G concentrations in spontaneous preterm labor with intact membranes and preterm PROM

Among patients with spontaneous preterm labor, those with IAI had a significantly higher median amniotic fluid concentration of sHLA-G than patients who delivered preterm without IAI (88.4 U/mL vs. 46.5 U/mL, respectively; $p<0.001$) and than those with spontaneous preterm labor with intact membranes who delivered at term (88.4 U/mL vs. 50.4 U/mL, respectively; $p<0.001$) (Figure 3). There were no differences in the median amniotic fluid sHLA-G concentration between patients with spontaneous preterm labor without IAI who delivered preterm and those who delivered at term (46.5 U/mL vs. 50.4 U/mL, respectively; $p=0.4$) (Figure 3).

Similarly, patients with preterm PROM with IAI had a significantly higher median amniotic fluid sHLA-G concentration than those without IAI (preterm PROM with IAI: 76.7 U/mL vs. preterm PROM without IAI: 46.6 U/mL; $p=0.004$) (Figure 4).

A significant but weak correlation was observed between amniotic fluid concentration of sHLA-G and those of IL-6 and WBC count in patients with spontaneous preterm labor and those with PPROM (Spearman's rho coefficient: IL-6: 0.31, $p<0.001$ and WBC count: 0.2, $p<0.001$). There was no significant correlation between the amniotic fluid concentrations of sHLA-G and glucose (Spearman's rho coefficient: glucose: -0.025 , $p=0.6$).

Amniotic fluid sHLA-G concentrations in patients with histologic chorioamnionitis

Among patients with spontaneous preterm labor who delivered within 72 hours from amniocentesis, 63 patients had placental pathology available and 51% (32/63) had evidence of placental inflammation. Patients with histologic chorioamnionitis and/or funisitis had a significantly higher median sHLA-G concentration in amniotic fluid than those without histologic inflammation (122.7 U/mL vs. 47.7 U/mL, respectively; $p<0.001$) (Figure 5).

DISCUSSION

Principal findings of the study

1) sHLA-G is a physiologic constituent of amniotic fluid, and its concentration did not change with gestational age; 2) in the presence of intra-amniotic infection/inflammation, patients with spontaneous PTL with intact membranes as well as those with preterm PROM had a significantly higher median amniotic fluid concentration of sHLA-G than that of those without intra-amniotic infection/inflammation; 3) similarly, patients with histologic chorioamnionitis and/or funisitis had a higher median amniotic fluid sHLA-G concentration than those without evidence of placental inflammation; 4) amniotic fluid sHLA-G concentrations were significantly correlated with indirect amniotic fluid markers for intra-amniotic infection/inflammation (WBC count and IL-6 concentrations); and 5) spontaneous labor at term was associated with a significant decrease in the median amniotic fluid sHLA-G concentration.

What is HLA-G?

The class I region of the major histocompatibility complex includes the HLA class Ia genes, that encode the classical high polymorphic transplantation antigens (HLA-A, -B, -C), and the nonclassical class Ib genes (HLA-E, -F, and -G).[50] HLA-G is similar in organization to the classical HLA-A, -B, and -C encoded proteins except that an in-frame termination codon prevents translation of a majority of the cytoplasmic region of the HLA-G polypeptide. The full-length HLA-G transcript encodes a protein with an overall homology of 86% to the HLA-A, -B, and -C protein sequence.[83–86] Although HLA-G has a similar structure to classic HLA Ia molecules, it has much lower polymorphism[87–90] and restricted capacity to translate to proteins.

The *HLA-G* gene was first reported by Geraghty and coworkers in 1987,[83] but it was not discovered that this gene encoded the class I molecule expressed in human trophoblasts until 1990.[91,92] The *HLA-G* gene is located within the major histocompatibility complex in the short arm of chromosome 6[93] and contains eight exons: 1) the first exon encodes the leader peptide; 2) the second, third and fourth exons encode the alpha-1, alpha-2 and alpha-3 regions of the protein, respectively; 3) the fifth exon encodes the transmembrane region, 4) the sixth and seventh exons encode the cytoplasmic tail; and 5) the eighth exon encodes the 3' untranslated region.[85] HLA-G is characterized by an expression pattern of seven isoforms: four membrane-bound isoforms (HLA-G1, -G2, -G3 and -G4) and three soluble isoforms (HLA-G5, -G6 and -G7)[52–55] that are generated by alternative splicing of a unique primary transcript.[56–58] HLA-G binds to three inhibitory receptors: immunoglobulin-like transcript-2 (ILT-2) and -4 (ILT-4) and killer immunoglobulin-like receptor (KIR) 2DL4. These receptors are differentially expressed depending of the immune cell type:[94] 1) ILT-2 is expressed in myeloid and lymphoid cells;[95–97] 2) ILT-4 only by myeloid cells;[98] and 3) KIR2DL4 is expressed by NK cells and CD8+ T cells.[99,100]

HLA-A, -B and -C show broad tissue expression, whereas HLA-G expression is highly tissue-restricted, placenta being one of the most important organs for HLA-G expression. [59–63] Extravillous trophoblast,[91,92,101] Hofbauer cells,[102] and endothelial cells from chorionic villi[103] express HLA-G. Interestingly, HLA-G expression has been observed in complete and partial hydatidiform moles as well as in ectopic pregnancies, suggesting that HLA-G expression in trophoblast cells is independent of embryonic development.[104] Besides expression in fetal tissues such as trophoblast cells, HLA-G constitutive expression was found only in adult thymic medulla,[105] cornea,[106] pancreatic islets,[107] and erythroid and endothelial-cell precursors.[108] However, HLA-G expression can be induced in cancers,[109,110] organ transplant,[111] multiple sclerosis,[112] inflammatory diseases,

[113,114] and viral infections.[115,116] The mRNA for HLA-G has been detected in several embryonic and adult tissues, including adult and fetal thymus,[117,118] fetal liver and eye,[56,119] adult spleen,[120] skin and keratinocytes,[121] but the protein has been reported to be restricted to trophoblast and choriocarcinoma cells.[92,122,123]

HLA-G and immune response

Maternal decidua and fetal trophoblasts contribute to create a tolerant environment for the fetus.[65,124,125] Specific mechanisms must exist to modulate and escape the maternal immune system in order to avoid fetal rejection,[126] however, these mechanisms are still poorly understood.

The HLA-G molecules may play a role regulating immune cells and potentially be an essential part in this immune interaction between mother and fetus.[65,125,127–133] Pazmany et al[134] demonstrated that expression of HLA-G is sufficient to protect trophoblast from lysis by activated natural killer (NK) cell lines and clones. Rouas-Freiss et al[135] demonstrated that cytotrophoblast cells strongly inhibit maternal uterine NK cell-mediated lysis in both semiallogeneic and allogeneic combinations, and that this HLA-G-mediated protection was inhibited by treatment of cytotrophoblasts with an HLA-G-specific monoclonal antibody. Le Gal et al[64] demonstrated that HLA-G inhibits cytotoxic T lymphocytes. HLA-G seems to be able to inhibit both cytotoxic T-lymphocyte response and NK cells,[64,136,137] as well as prevent proliferation of CD4+T cells[138–141] and induce CD8+T apoptosis through the Fas/FasL pathway.[126,140,142,143] Similarly, Fournel et al[142] showed that binding of sHLA-G induces CD8+T cells death through the Fas/FasL pathway. Feger et al[144] identified a novel population of CD4 and CD8 T cells characterized by cell surface expression of HLA-G with regulatory properties that may have implications for the mechanisms of inflammation, autoimmunity, and also tumor immune surveillance. The correlation of HLA-G T cells with acute central nervous system inflammation, such as multiple sclerosis relapse, supports the hypothesis of HLA-G T cells presumed immunoregulatory role in modulating inflammatory responses.[144]

Soluble HLA-G present at the maternal-fetal interface may contribute to immune tolerance by killing T-cells. Elevated concentration of circulating NK cells have been linked to reproductive failure.[145,146] Soluble HLA-G isoforms, likely membrane-bound HLA-G molecules, were found to function as immuno-tolerant molecules by inhibiting NK cells function.[64] Moreover, Petroff et al[147] were the first to identify the two HLA class I-binding inhibitory receptors, ILT2 and ILT4, on macrophages within maternal decidua, suggesting that class I HLA molecules expressed at the maternal-fetal interface could impact the function of decidual macrophages. This immunomodulator function led to the suggestion that HLA-G may play a role in tolerance preventing immunorejection of the semiallogeneic fetus by the maternal immune system, probably contributing to graft tolerance and tumor escape.[65]

sHLA-G in normal pregnancy

Contradictory results have been reported regarding plasma/serum sHLA-G concentrations in normal pregnancy. A decade ago, Rebmann et al[74] found sHLA-G in almost all samples tested. There were no differences in the plasma sHLA-G concentration between men and non-pregnant women. Similarly, no differences were observed between non-pregnant and pregnant women at delivery, although information about gestational age and the presence or absence of labor at the time of sample collection was not provided. The umbilical cord plasma concentration of sHLA-G was significantly lower compared to that of maternal plasma. Puppo et al[73] did not find differences in serum sHLA-G concentrations between non-pregnant women, pregnant women at different gestational ages, and umbilical cord

samples. In contrast, Hunt and Ober et al[148] reported that non-pregnant women had significantly lower serum sHLA-G concentrations than pregnant women at any gestational age, and that serum sHLA-G concentrations do not change with advancing gestational age. These findings are consistent with those published in two recent studies including serum[76] and plasma[58] samples. In contrast, Athanassakis et al[149] reported that non-pregnant women have significantly higher serum sHLA-G concentrations than pregnant women, and that serum concentrations of sHLA-G progressively increase as gestation progresses. However, in a large cohort of non-pregnant and normal pregnant women in each trimester, Steinborn et al[69] found that plasma concentrations of sHLA-G significantly decreases from the first trimester until the end of pregnancy. It has been proposed that the use of plasma or serum for determination of sHLA-G concentrations may account, in part, for discrepancies observed among studies.[150]

HLA-G and sHLA-G in pregnancy complications

Inadequate maternal immune recognition and response may be associated with maternal-fetal histocompatibility.[128] There is a solid body of evidence supporting a role for HLA-G/sHLA-G in the pathophysiology of several obstetric complications[65–69] such as recurrent spontaneous abortion,[58,149,151–167] preeclampsia, intrauterine growth restriction, placental abruption, preterm labor and preterm PROM.

Preeclampsia—It has been proposed that defective HLA-G expression may be related to the vascular and immune abnormalities characteristics of preeclampsia.[168,169] Hara et al[170] studied HLA-G protein expression by immunohistochemistry in extravillous trophoblasts from patients with preeclampsia and those with a normal pregnancy. All the extravillous trophoblasts from normal pregnancies were stained for HLA-G protein, whereas attenuated expression of HLA-G protein was observed in patients with preeclampsia. Similar results were observed for placental lysates[171] and RNA expression[168] in cases with preeclampsia. Moreover, an association between fetal HLA-G genotype (e.g. +14bp/+14bp) and the higher risk of preeclampsia has been observed in primiparas.[172]

Several studies have found that the maternal plasma/serum concentrations of sHLA-G of patients with preeclampsia are significantly lower than that of normal pregnant women at the time of the disease.[66,171] Of interest, these differences can be observed even before the clinical diagnosis of preeclampsia. Yie et al[173] demonstrated that patients who subsequently will develop preeclampsia have plasma sHLA-G concentrations in the first, second and third trimesters significantly lower than that of matched normal pregnant women, and suggested that sHLA-G may be a useful molecule for predicting preeclampsia. Steinborn et al[69] reported similar results for the second trimester of pregnancy but, unexpectedly, did not find significant differences in the maternal plasma sHLA-G concentration between normal pregnant women and those with preeclampsia at the time of diagnosis of the disease. This finding is in agreement with the results of a study that did not find significantly different HLA-G expression by immunohistochemistry on chorionic and extravillous cytotrophoblast between patients with severe preeclampsia delivered preterm and patients with normal pregnancies delivered at term.[174]

Intrauterine growth restriction—Steinborn et al[69] also found lower maternal plasma sHLA-G concentrations in the second trimester in patients who subsequently developed intrauterine growth restriction compared to normal pregnancies; however, no significant differences were observed in the third trimester.[69] A significant association between an HLA-G genotype homozygous for the presence of a 14 base pair polymorphism and increased birth weight has been reported.[175] Yet, a null mutation in exon 3 of HLA-G has

not been associated with increased risk for preeclampsia or intrauterine growth restriction. [176]

Placental abruption—Patients with placental abruption have a significantly lower plasma concentration of sHLA-G than patients with normal pregnancies.[68]

Preterm labor and Preterm PROM—Steinborn et al[69] also measured sHLA-G in patients with spontaneous preterm labor and in those with preterm PROM. The authors reported significantly higher plasma concentrations of sHLA-G in patients with preterm labor compared to normal pregnancies and those with preterm PROM. No differences were observed between normal pregnant women and patients with preterm PROM.

HLA-G and sHLA-G in amniotic fluid

The results reported herein demonstrate that sHLA-G is a physiological constituent of the amniotic fluid, since it was detected in all but two amniotic fluid samples included in this study. This finding is in agreement with previous reports. McMaster et al[72] reported the presence of HLA-G in all amniotic fluid samples collected at 16–18 weeks of gestation and in the third trimester. Rebmann et al[74] measured sHLA-G concentrations in amniotic fluid samples obtained from mid-trimester amniocentesis, as well as in plasma from maternal and cord blood obtained at term, and found that sHLA-G concentrations in amniotic fluid in the mid-trimester are significantly lower than that of maternal plasma. Similarly, the maternal serum concentrations of sHLA-G were significantly higher than that of amniotic fluid from normal pregnancies and patients with preeclampsia.[66] In contrast, Puppo et al[73] found that the concentration of sHLA-G in the amniotic fluid is significantly higher than in maternal serum, and also significantly higher than the amniotic fluid concentration of sHLA-ABC. The authors suggested that amniotic epithelial cells, which express both HLA-ABC and HLA-G antigens, may preferentially secrete sHLA-G molecules.[73]

In amniotic fluid from mid-trimester amniocentesis obtained due to advanced maternal age, Emmer et al[75] found that the concentrations of sHLA-G were higher in women with male fetuses than that of those with female fetuses. These differences were not observed in the present study. The same authors also reported that the amniotic fluid concentrations of sHLA-G were significantly lower in patients with neural tube defects than that of controls, [177] and proposed that this finding may reflect an altered cell-mediated immunity in those pregnancies, which might be associated to folate deficiency or thymus dysplasia.

In the study reported herein, although there was a trend toward reduction by the end of pregnancy, no significant differences were observed in the amniotic fluid concentrations of sHLA-G between patients in the mid-trimester and that of those at term not in labor. This is in contrast with the results of Hackmon et al,[76] who found that amniotic fluid sHLA-G1 concentrations were lower in samples obtained from patients at term who underwent cesarean section compared to that of those from mid-trimester amniocentesis. The reasons for the discrepancies among studies are unclear, although it is possible that the sample size and methods used to determine sHLA-G may explain the conflictive results. The authors proposed that lower amniotic fluid concentrations of sHLA-G toward term may reflect a maternal immune response against fetal trophoblast, which may lead to parturition. This finding has not been observed in maternal blood, since there are no significant changes in sHLA-G serum concentrations among first, second and third trimester.[73,148]

Interestingly, we found that spontaneous labor at term was associated with lower amniotic fluid concentrations of sHLA-G than that of those from women not in labor. It is possible that sHLA-G plays a role as immunomodulator in early pregnancy, and that declining

amniotic fluid sHLA-G concentrations near term may contribute to the initiation of parturition.

Although the main source of maternal serum sHLA-G is probably the extravillous cytotrophoblast, the sources of sHLA-G in the amniotic fluid still needs to be elucidated.[66] It has been proposed that production of soluble HLA-G may occur in amnion and decidual trophoblast cells[177] and amnion epithelium.[178] Recently, it has been shown that fresh and cultured amniotic fluid cells express soluble forms of HLA-I and HLA-G.[179,180] Interestingly, both shed HLA-G1 and HLA-G5 have been detected in different body fluids such as serum from pregnant and non-pregnant women, patients with cancer or transplants, and even in plasma from men.[73,74,111,181,182] This suggest that, beside trophoblast, circulating HLA-G may have other sources. Monocytes have a very low HLA-G expression, but it can be induced to some extent in these cells by cytokines such as Interferon (IFN)- γ . [102,183]

sHLA-G is significantly elevated in intra-amniotic infection and inflammation

This study is the first to demonstrate significantly higher amniotic fluid concentrations of sHLA-G in pregnancies associated with intra-amniotic infection/inflammation, which is one of the most important mechanisms of disease associated to spontaneous preterm labor with intact membranes or preterm PROM. The findings reported herein suggest that sHLA-G participates in the host response to microbial invasion of the amniotic cavity. Indeed, among patients with spontaneous preterm labor and intact membranes and those with preterm PROM who had intra-amniotic infection/inflammation, the median amniotic fluid sHLA-G concentration was almost 2-fold higher than that of those without intra-amniotic infection/inflammation. These findings are supported by the results of patients with histologic chorioamnionitis and/or funisitis, who had a higher median amniotic fluid sHLA-G concentration than those without evidence of placental inflammation.

Increased expression of HLA-G has been reported in infectious diseases,[70] mainly in viral infections.[115,116,184] In addition, Monneret et al[71] measured plasma sHLA-G5 concentrations in consecutive patients with septic shock. The authors found that sHLA-G5 concentrations increased 24–48 hours from the onset of septic shock, and a significant difference between survivors and non-survivors was observed at this time, remaining significant until day seven. Interestingly, non-survivors were associated with lower concentrations of sHLA-G5 than that of those who survived. The authors concluded that sHLA-G5 may have an important role in negative feedback signals that limit the process of inflammation during septic shock.[71]

A solid body of evidence supports an involvement of HLA-G in autoimmune and inflammatory diseases.[70] In fact, HLA-G expression has been described in the skin, pancreas, digestive tract, muscle and central nervous system: 1) HLA-G expression was demonstrated in patients with atopic dermatitis and psoriasis;[57,113,114,185] 2) HLA-G expression is enhanced in cases of celiac disease[186] and ulcerative colitis, while there is almost no expression in cases of Crohn's disease.[187,188] It has been proposed that differential expression of HLA-G provides a potential way to distinguish between ulcerative colitis and Crohn's disease;[187] 3) HLA-G expression in the human pancreas is restricted to insulin, glucagon, and ductal cells, and is upregulated in the presence of an inflammatory stimulus;[107] and 4) a role for HLA-G has been proposed in multiple sclerosis,[189–191] acute neuroinflammatory disorders,[144] asthma,[192–194] rheumatoid arthritis,[195] and myositis.[144,196,197]

HLA-G5 and HLA-G6 stimulate TGF- β 1, an anti-inflammatory cytokine, in monocyte and monocyte-derived macrophage models,[198,199] and low doses of HLA-G5 induce IL-10

secretion.[198,199] In cultured trophoblast cells, Moreau et al[200] showed that IL-10 enhances HLA-G transcription and up-regulate HLA-G cell surface expression in peripheral blood monocytes. Thus, induction of HLA-G expression by IL-10 on monocytes may play a role in down-regulation of the immune response.[200] Our group demonstrated that spontaneous term and preterm parturition, as well as intra-amniotic infection/inflammation, is associated with increased amniotic fluid concentrations of IL-10.[201] We suggest that IL-10 has a role in the regulation of the immune response *in vivo* by initiating actions that dampen inflammation.[201] Kapasi et al[202] demonstrated that exposure to HLA-G is associated with *in vitro* suppression of allo-cytotoxic T lymphocytes and the development of a Th2-type cytokine response, leading the authors to propose that HLA-G may contribute to a putative protective role in pregnancy.[202] HLA-G participates in the imbalance toward a Th2-type immune response during pregnancy[185] by inducing the secretion of anti-inflammatory cytokines such as IL-3, IL-4[203] and IL-10,[202] and down-regulating the production of IFN- γ and TNF- α . [203] Therefore, HLA-G has been proposed as a negative feedback signal that limits the process of inflammation.[185]

In conclusion, amniotic fluid concentrations of sHLA-G are elevated in preterm parturition associated intra-amniotic infection/inflammation as well as histologic chorioamnionitis. We propose that sHLA-G may participate in the regulation of the host immune response against intra-amniotic infection.

Acknowledgments

This research was supported by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS. The authors would like to acknowledge the contribution of Dr. Carole Ober in the conduction of this work.

Reference List

1. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. The preterm parturition syndrome. *BJOG*. 2006; 113(Suppl 3):17–42. [PubMed: 17206962]
2. Naeye RL, Ross SM. Amniotic fluid infection syndrome. *Clin.Obstet.Gynaecol*. 1982; 9:593–607. [PubMed: 6756749]
3. Minkoff H. Prematurity: infection as an etiologic factor. *Obstet.Gynecol*. 1983; 62:137–144. [PubMed: 6346172]
4. Romero R, Mazor M, Wu YK, Sirtori M, Oyarzun E, Mitchell MD, Hobbins JC. Infection in the pathogenesis of preterm labor. *Semin.Perinatol*. 1988; 12:262–279. [PubMed: 3065940]
5. Romero R, Mazor M. Infection and preterm labor. *Clin.Obstet.Gynecol*. 1988; 31:553–584. [PubMed: 3066544]
6. Ledger WJ. Infection and premature labor. *Am.J.Perinatol*. 1989; 6:234–236. [PubMed: 2712921]
7. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, Sabo V, Athanassiadis AP, Hobbins JC. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. *Am.J.Obstet.Gynecol*. 1989; 161:817–824. [PubMed: 2675611]
8. Gibbs RS, Romero R, Hillier SL, Eschenbach DA, Sweet RL. A review of premature birth and subclinical infection. *Am.J.Obstet.Gynecol*. 1992; 166:1515–1528. [PubMed: 1595807]
9. Brocklehurst P. Infection and preterm delivery. *BMJ*. 1999; 318:548–549. [PubMed: 10037609]
10. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. *N.Engl.J.Med*. 2000; 342:1500–1507. [PubMed: 10816189]
11. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. *Ment.Retard.Dev.Disabil.Res.Rev*. 2002; 8:3–13. [PubMed: 11921380]
12. Hirsch E, Wang H. The molecular pathophysiology of bacterially induced preterm labor: insights from the murine model. *J Soc.Gynecol Investig*. 2005; 12:145–155.

13. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, Jun JK. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am.J.Obstet.Gynecol.* 2001; 185:1130–1136. [PubMed: 11717646]
14. Kim KW, Romero R, Park HS, Park CW, Shim SS, Jun JK, Yoon BH. A rapid matrix metalloproteinase-8 bedside test for the detection of intraamniotic inflammation in women with preterm premature rupture of membranes. *Am J Obstet.Gynecol.* 2007; 197:292–295. [PubMed: 17826425]
15. Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edwin SS, Berry SM. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. *Am.J.Obstet.Gynecol.* 1998; 179:186–193. [PubMed: 9704786]
16. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am.J.Obstet.Gynecol.* 1998; 179:194–202. [PubMed: 9704787]
17. Yoon BH, Romero R, Kim CJ, Jun JK, Gomez R, Choi JH, Syn HC. Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity. *Am.J.Obstet.Gynecol.* 1995; 172:960–970. [PubMed: 7892891]
18. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. *Pediatr.Res.* 1997; 42:1–8. [PubMed: 9212029]
19. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. *Am.J.Obstet.Gynecol.* 1997; 177:825–830. [PubMed: 9369827]
20. Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH, Kim IO. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. *Am.J.Obstet.Gynecol.* 1997; 177:19–26. [PubMed: 9240577]
21. Leviton A, Paneth N, Reuss ML, Susser M, Allred EN, Dammann O, Kuban K, Van Marter LJ, Pagano M, Hegyi T, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. *Pediatr.Res.* 1999; 46:566–575. [PubMed: 10541320]
22. Yoon BH, Romero R, Kim KS, Park JS, Ki SH, Kim BI, Jun JK. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. *Am.J.Obstet.Gynecol.* 1999; 181:773–779. [PubMed: 10521727]
23. Dammann O, Leviton A. Role of the fetus in perinatal infection and neonatal brain damage. *Curr.Opin.Pediatr.* 2000; 12:99–104. [PubMed: 10763757]
24. Yoon BH, Romero R, Park JS, Kim CJ, Kim SH, Choi JH, Han TR. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. *Am.J.Obstet.Gynecol.* 2000; 182:675–681. [PubMed: 10739529]
25. Gibbs RS. The relationship between infections and adverse pregnancy outcomes: an overview. *Ann.Periodontol.* 2001; 6:153–163. [PubMed: 11887458]
26. Patrick LA, Smith GN. Proinflammatory cytokines: a link between chorioamnionitis and fetal brain injury. *J.Obstet.Gynaecol.Can.* 2002; 24:705–709. [PubMed: 12360365]
27. Yoon BH, Romero R, Shim JY, Lim JH, Choe G, Kadar N, Park M. “Atypical” chronic lung disease of the newborn is linked to fetal systemic inflammation. *Am.J.Obstet.Gynecol.* 2002; 187:S129.
28. Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. *BJOG.* 2003; 110(Suppl 20):124–127. [PubMed: 12763129]
29. Hagberg H, Mallard C, Jacobsson B. Role of cytokines in preterm labour and brain injury. *BJOG.* 2005; 112(Suppl 1):16–18. [PubMed: 15715588]
30. Bashiri A, Burstein E, Mazor M. Cerebral palsy and fetal inflammatory response syndrome: a review. *J Perinat.Med.* 2006; 34:5–12. [PubMed: 16489880]
31. Iams JD, Johnson FF, Sonek J, Sachs L, Gebauer C, Samuels P. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance. *Am J Obstet Gynecol.* 1995; 172:1097–1103. [PubMed: 7726247]

32. Romero R, Espinoza J, Erez O, Hassan S. The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? *Am J Obstet.Gynecol.* 2006; 194:1–9. [PubMed: 16389003]
33. Phelan JP, Park YW, Ahn MO, Rutherford SE. Polyhydramnios and perinatal outcome. *J Perinatol.* 1990; 10:347–350. [PubMed: 2277279]
34. Romero R, Mazor M, Avila C, Quintero R, Munoz H. Uterine “allergy”: A novel mechanism for preterm labor. *Am J Obstet Gynecol.* 1991; 164:375.
35. Garfield RE, Bytautiene E, Vedernikov YP, Marshall JS, Romero R. Modulation of rat uterine contractility by mast cells and their mediators. *Am.J.Obstet.Gynecol.* 2000; 183:118–125. [PubMed: 10920318]
36. Bytautiene E, Vedernikov YP, Saade GR, Romero R, Garfield RE. Endogenous mast cell degranulation modulates cervical contractility in the guinea pig. *Am.J.Obstet.Gynecol.* 2002; 186:438–445. [PubMed: 11904604]
37. Bytautiene E, Romero R, Vedernikov YP, El-Zeky F, Saade GR, Garfield RE. Induction of premature labor and delivery by allergic reaction and prevention by histamine H1 receptor antagonist. *Am J Obstet.Gynecol.* 2004; 191:1356–1361. [PubMed: 15507965]
38. Csapo AI, Pohanka O, Kaihola HL. Progesterone deficiency and premature labour. *Br.Med.J.* 1974; 1:137–140. [PubMed: 4812406]
39. Check JH, Lee G, Epstein R, Vetter B. Increased rate of preterm deliveries in untreated women with luteal phase deficiencies. Preliminary report. *Gynecol.Obstet.Invest.* 1992; 33:183–184. [PubMed: 1612531]
40. Mazor M, Hershkovitz R, Chaim W, Levy J, Sharony Y, Leiberman JR, Glezerman M. Human preterm birth is associated with systemic and local changes in progesterone/17 beta-estradiol ratios. *Am.J.Obstet.Gynecol.* 1994; 171:231–236. [PubMed: 8030704]
41. Fidel PI Jr. Romero R, Maymon E, Hertelendy F. Bacteria-induced or bacterial product-induced preterm parturition in mice and rabbits is preceded by a significant fall in serum progesterone concentrations. *J.Matern.Fetal Med.* 1998; 7:222–226. [PubMed: 9775989]
42. Arias F, Rodriguez L, Rayne SC, Kraus FT. Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. *Am.J.Obstet.Gynecol.* 1993; 168:585–591. [PubMed: 8438933]
43. Arias F, Victoria A, Cho K, Kraus F. Placental histology and clinical characteristics of patients with preterm premature rupture of membranes. *Obstet.Gynecol.* 1997; 89:265–271. [PubMed: 9015033]
44. Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S, Thaler HT, Romero R. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. *Am.J.Obstet.Gynecol.* 2002; 187:1137–1142. [PubMed: 12439491]
45. Kim YM, Bujold E, Chaiworapongsa T, Gomez R, Yoon BH, Thaler HT, Rotmensch S, Romero R. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. *Am.J.Obstet.Gynecol.* 2003; 189:1063–1069. [PubMed: 14586356]
46. Romero R, Sepulveda W, Baumann P, Yoon BH, Brandt F, Gomez R, Mazor M, Sorokin Y, Cotton D. The preterm labor syndrome: Biochemical, cytologic, immunologic, pathologic, microbiologic, and clinical evidence that preterm labor is a heterogeneous disease. *Am J.Obstet.Gynecol.* 1993; 168:288.
47. Kilpatrick DC. Immune mechanisms and pre-eclampsia. *Lancet.* 1987; 2:1460–1461. [PubMed: 2892017]
48. McLean JM. Early embryo loss. *Lancet.* 1987; 1:1033–1034. [PubMed: 2883371]
49. Aksel S. Immunologic aspects of reproductive diseases. *JAMA.* 1992; 268:2930–2934. [PubMed: 1433710]
50. Schmidt CM, Orr HT. A physical linkage map of HLA-A, -G, -7.5p, and -F. *Hum.Immunol.* 1991; 31:180–185. [PubMed: 1890019]
51. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, LeMaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. *Blood.* 2008; 111:4862–4870. [PubMed: 18334671]

52. Hunt JS, Pace JL, Morales PJ, Ober C. Immunogenicity of the soluble isoforms of HLA-G. *Mol.Hum.Reprod.* 2003; 9:729–735. [PubMed: 14561816]
53. Sargent IL. Does 'soluble' HLA-G really exist? Another twist to the tale. *Mol.Hum.Reprod.* 2005; 11:695–698. [PubMed: 16330473]
54. Pace JL, Morales PJ, Phillips TA, Hunt JS. Analysis of the soluble isoforms of HLA-G mRNAs and proteins. *Methods Mol.Med.* 2006; 122:181–203. [PubMed: 16511982]
55. Rebmann V, LeMaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H. Quantification and identification of soluble HLA-G isoforms. *Tissue Antigens.* 2007; 69(Suppl 1):143–149. [PubMed: 17445190]
56. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. *Proc.Natl.Acad.Sci.U.S.A.* 1992; 89:3947–3951. [PubMed: 1570318]
57. Carosella ED, Moreau P, Le MJ, Le DM, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. *Adv.Immunol.* 2003; 81:199–252. [PubMed: 14711057]
58. Alegre E, az-Lagares A, LeMaoult J, Lopez-Moratalla N, Carosella ED, Gonzalez A. Maternal antigen presenting cells are a source of plasmatic HLA-G during pregnancy: longitudinal study during pregnancy. *Hum.Immunol.* 2007; 68:661–667. [PubMed: 17678720]
59. Yelavarthi KK, Fishback JL, Hunt JS. Analysis of HLA-G mRNA in human placental and extraplacental membrane cells by in situ hybridization. *J Immunol.* 1991; 146:2847–2854. [PubMed: 2016528]
60. Chu W, Fant ME, Geraghty DE, Hunt JS. Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. *Hum.Immunol.* 1998; 59:435–442. [PubMed: 9684993]
61. Le Bouteiller P, Solier C, Proll J, guerre-Girr M, Fournel S, Lenfant F. Placental HLA-G protein expression in vivo: where and what for? *Hum.Reprod.Update.* 1999; 5:223–233. [PubMed: 10438107]
62. Le Bouteiller P. HLA-G in the human placenta: expression and potential functions. *Biochem.Soc.Trans.* 2000; 28:208–212. [PubMed: 10816129]
63. Morales PJ, Pace JL, Platt JS, Phillips TA, Morgan K, Fazleabas AT, Hunt JS. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. *J Immunol.* 2003; 171:6215–6224. [PubMed: 14634138]
64. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. *Int.Immunol.* 1999; 11:1351–1356. [PubMed: 10421792]
65. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. *FASEB J.* 2005; 19:681–693. [PubMed: 15857883]
66. Hackmon R, Koifman A, Hyodo H, Glickman H, Sheiner E, Geraghty DE. Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia. *Am J.Obstet.Gynecol.* 2007; 197:255. [PubMed: 17826409]
67. Steinborn A, Rebmann V, Scharf A, Sohn C, Grosse-Wilde H. Soluble HLA-DR levels in the maternal circulation of normal and pathologic pregnancy. *Am.J.Obstet.Gynecol.* 2003; 188:473–479. [PubMed: 12592258]
68. Steinborn A, Rebmann V, Scharf A, Sohn C, Grosse-Wilde H. Placental abruption is associated with decreased maternal plasma levels of soluble HLA-G. *J.Clin.Immunol.* 2003; 23:307–314. [PubMed: 12959223]
69. Steinborn A, Varkonyi T, Scharf A, Bahlmann F, Klee A, Sohn C. Early detection of decreased soluble HLA-G levels in the maternal circulation predicts the occurrence of preeclampsia and intrauterine growth retardation during further course of pregnancy. *Am J.Reprod.Immunol.* 2007; 57:277–286. [PubMed: 17362389]
70. Carosella ED, Moreau P, LeMaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. *Trends Immunol.* 2008; 29:125–132. [PubMed: 18249584]

71. Monneret G, Voirin N, Krawice-Radanne I, Bohe J, Lepape A, Rouas-Freiss N, Carosella ED. Soluble human leukocyte antigen-G5 in septic shock: marked and persisting elevation as a predictor of survival. *Crit Care Med*. 2007; 35:1942–1947. [PubMed: 17581490]
72. McMaster M, Zhou Y, Shorter S, Kapasi K, Geraghty D, Lim KH, Fisher S. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. *J.Immunol*. 1998; 160:5922–5928. [PubMed: 9637505]
73. Puppo F, Costa M, Contini P, Brenci S, Cevasco E, Ghio M, Norelli R, Bensussan A, Capitanio GL, Indiveri F. Determination of soluble HLA-G and HLA-A, -B, and -C molecules in pregnancy. *Transplant.Proc*. 1999; 31:1841–1843. [PubMed: 10371968]
74. Rebmann V, Pfeiffer K, Passler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. *Tissue Antigens*. 1999; 53:14–22. [PubMed: 10082427]
75. Emmer PM, Steegers EA, van Lierop MJ, Loke YW, van der MA, Joosten I. Levels of soluble HLA-G in amniotic fluid are related to the sex of the offspring. *Eur.J.Immunogenet*. 2003; 30:163–164. [PubMed: 12648287]
76. Hackmon R, Hallak M, Krup M, Weitzman D, Sheiner E, Kaplan B, Weinstein Y. HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy. *Fetal Diagn.Ther*. 2004; 19:404–409. [PubMed: 15305096]
77. Kusanovic JP, Romero R, Mazaki-Tovi S, Chaiworapongsa T, Mittal P, Gotsch F, Erez O, Vaisbuch E, Edwin SS, Than NG, et al. Resistin in amniotic fluid and its association with intra-amniotic infection and inflammation. *J Matern.Fetal Neonatal Med*. 2008; 21:902–916. [PubMed: 19065463]
78. Pacora P, Chaiworapongsa T, Maymon E, Kim YM, Gomez R, Yoon BH, Ghezzi F, Berry SM, Qureshi F, Jacques SM, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. *J.Matern.Fetal Neonatal Med*. 2002; 11:18–25. [PubMed: 12380603]
79. Romero R, Emamian M, Quintero R, Wan M, Hobbins JC, Mazor M, Edberg S. The value and limitations of the Gram stain examination in the diagnosis of intraamniotic infection. *Am.J.Obstet.Gynecol*. 1988; 159:114–119. [PubMed: 2456013]
80. Romero R, Jimenez C, Lohda AK, Nores J, Hanaoka S, Avila C, Callahan R, Mazor M, Hobbins JC, Diamond MP. Amniotic fluid glucose concentration: a rapid and simple method for the detection of intraamniotic infection in preterm labor. *Am.J.Obstet.Gynecol*. 1990; 163:968–974. [PubMed: 1698338]
81. Romero R, Quintero R, Nores J, Avila C, Mazor M, Hanaoka S, Hagay Z, Merchant L, Hobbins JC. Amniotic fluid white blood cell count: a rapid and simple test to diagnose microbial invasion of the amniotic cavity and predict preterm delivery. *Am.J.Obstet.Gynecol*. 1991; 165:821–830. [PubMed: 1951538]
82. Bonferroni C. Il calcolo delle assicurazioni su gruppi di teste. 1935:13–60.
83. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. *Proc.Natl.Acad.Sci.U.S.A*. 1987; 84:9145–9149. [PubMed: 3480534]
84. Parham P, Lomen CE, Lawlor DA, Ways JP, Holmes N, Coppin HL, Salter RD, Wan AM, Ennis PD. Nature of polymorphism in HLA-A, -B, and -C molecules. *Proc.Natl.Acad.Sci.U.S.A*. 1988; 85:4005–4009. [PubMed: 3375250]
85. Schmidt CM, Orr HT. Maternal/fetal interactions: the role of the MHC class I molecule HLA-G. *Crit Rev.Immunol*. 1993; 13:207–224. [PubMed: 8110376]
86. Carosella ED, Dausset J, Kirszenbaum M. HLA-G revisited. *Immunol.Today*. 1996; 17:407–409. [PubMed: 8854556]
87. van der Ven K, Ober C. HLA-G polymorphisms in African Americans. *J Immunol*. 1994; 153:5628–5633. [PubMed: 7989762]
88. Ober C, Rosinsky B, Grimsley C, van, d V, Robertson A, Runge A. Population genetic studies of HLA-G: allele frequencies and linkage disequilibrium with HLA-A1. *J Reprod.Immunol*. 1996; 32:111–123. [PubMed: 9023816]

89. Ober C, Aldrich CL. HLA-G polymorphisms: neutral evolution or novel function? *J Reprod.Immunol.* 1997; 36:1–21. [PubMed: 9430736]
90. van der Ven K, Skrablin S, Ober C, Krebs D. HLA-G polymorphisms: ethnic differences and implications for potential molecule function. *Am J Reprod.Immunol.* 1998; 40:145–157. [PubMed: 9764358]
91. Ellis SA, Palmer MS, McMichael AJ. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA Class I molecule. *J.Immunol.* 1990; 144:731–735. [PubMed: 2295808]
92. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. *Science.* 1990; 248:220–223. [PubMed: 2326636]
93. Koller BH, Geraghty DE, DeMars R, Duvick L, Rich SS, Orr HT. Chromosomal organization of the human major histocompatibility complex class I gene family. *J Exp.Med.* 1989; 169:469–480. [PubMed: 2562983]
94. Favier B, LeMaout J, Carosella ED. Functions of HLA-G in the immune system. *Tissue Antigens.* 2007; 69(Suppl 1):150–152. [PubMed: 17445191]
95. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. *J Exp.Med.* 1997; 186:1809–1818. [PubMed: 9382880]
96. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. *Immunity.* 1997; 7:273–282. [PubMed: 9285411]
97. Saverino D, Fabbi M, Ghiotto F, Merlo A, Bruno S, Zarcone D, Tenca C, Tiso M, Santoro G, Anastasi G, et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. *J Immunol.* 2000; 165:3742–3755. [PubMed: 11034379]
98. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. *J Immunol.* 1998; 160:3096–3100. [PubMed: 9531263]
99. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C, Bertone S, Moretta A, Moretta L, Mingari MC. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. *Proc.Natl.Acad.Sci.U.S.A.* 1999; 96:5674–5679. [PubMed: 10318943]
100. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. *J Exp.Med.* 1999; 189:1093–1100. [PubMed: 10190900]
101. King A, Boocock C, Sharkey AM, Gardner L, Beretta A, Siccardi AG, Loke YW. Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. *J Immunol.* 1996; 156:2068–2076. [PubMed: 8690894]
102. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. *J.Immunol.* 1996; 156:4224–4231. [PubMed: 8666791]
103. Blaschitz A, Lenfant F, Mallet V, Hartmann M, Bensussan A, Geraghty DE, Le BP, Dohr G. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. *Eur.J Immunol.* 1997; 27:3380–3388. [PubMed: 9464826]
104. Rabreau M, Rouas-Freiss N, Landi M, Le DC, Carosella ED. HLA-G expression in trophoblast cells is independent of embryonic development. *Hum.Immunol.* 2000; 61:1108–1112. [PubMed: 11137214]
105. Mallet V, Fournel S, Schmitt C, Campan A, Lenfant F, Le BP. Primary cultured human thymic epithelial cells express both membrane-bound and soluble HLA-G translated products. *J.Reprod.Immunol.* 1999; 43:225–234. [PubMed: 10479058]
106. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. *Hum.Immunol.* 2003; 64:1039–1044. [PubMed: 14602233]

107. Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. *Diabetes*. 2006; 55:1214–1222. [PubMed: 16644675]
108. Menier C, Rabreau M, Challier JC, Le DM, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. *Blood*. 2004; 104:3153–3160. [PubMed: 15284117]
109. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. *Proc.Natl.Acad.Sci.U.S.A.* 1998; 95:4510–4515. [PubMed: 9539768]
110. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? *Cancer Res*. 2005; 65:10139–10144. [PubMed: 16287995]
111. Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication of HLA-G molecule in heart-graft acceptance. *Lancet*. 2000; 355:2138. [PubMed: 10902633]
112. Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. *Brain*. 2005; 128:2689–2704. [PubMed: 16123145]
113. Aractingi S, Briand N, Le DC, Viguier M, Bachelez H, Michel L, Dubertret L, Carosella ED. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? *Am.J.Pathol.* 2001; 159:71–77. [PubMed: 11438456]
114. Khosrotehrani K, Le DC, Reynaud-Mendel B, Dubertret L, Carosella ED, Aractingi S. HLA-G expression in atopic dermatitis. *J.Invest Dermatol.* 2001; 117:750–752. [PubMed: 11564188]
115. Lozano JM, Gonzalez R, Kindelan JM, Rouas-Freiss N, Caballos R, Dausset J, Carosella ED, Pena J. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. *AIDS*. 2002; 16:347–351. [PubMed: 11834945]
116. Lafon M, Prehaud C, Megret F, Lafage M, Mouillot G, Roa M, Moreau P, Rouas-Freiss N, Carosella ED. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. *J.Virol.* 2005; 79:15226–15237. [PubMed: 16306594]
117. Shukla H, Swaroop A, Srivastava R, Weissman SM. The mRNA of a human class I gene HLA G/HLA 6.0 exhibits a restricted pattern of expression. *Nucleic Acids Res*. 1990; 18:2189. [PubMed: 2336406]
118. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. *J Exp.Med.* 1997; 186:289–298. [PubMed: 9221758]
119. Houlihan JM, Biro PA, Fergar-Payne A, Simpson KL, Holmes CH. Evidence for the expression of non-HLA-A,-B,-C class I genes in the human fetal liver. *J.Immunol.* 1992; 149:668–675. [PubMed: 1624808]
120. Onno M, Guillaudeux T, Amiot L, Renard I, Drenou B, Hirel B, Girr M, Semana G, Le BP, Fauchet R. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. *Hum.Immunol.* 1994; 41:79–86. [PubMed: 7836069]
121. Ulbrecht M, Rehberger B, Strobel I, Messer G, Kind P, Degitz K, Bieber T, Weiss EH. HLA-G: expression in human keratinocytes in vitro and in human skin in vivo. *Eur.J.Immunol.* 1994; 24:176–180. [PubMed: 8020553]
122. Chumbley G, King A, Gardner L, Howlett S, Holmes N, Loke YW. Generation of an antibody to HLA-G in transgenic mice and demonstration of the tissue reactivity of this antibody. *J.Reprod.Immunol.* 1994; 27:173–186. [PubMed: 7738907]
123. Hammer A, Hutter H, Dohr G. HLA class I expression on the materno-fetal interface. *Am.J.Reprod.Immunol.* 1997; 38:150–157. [PubMed: 9325485]
124. Lanier LL. Natural killer cells fertile with receptors for HLA-G? *Proc.Natl.Acad.Sci.U.S.A.* 1999; 96:5343–5345. [PubMed: 10318882]
125. Hunt JS, Petroff MG, Morales P, Sedlmayr P, Geraghty DE, Ober C. HLA-G in reproduction: studies on the maternal-fetal interface. *Hum.Immunol.* 2000; 61:1113–1117. [PubMed: 11137215]

126. Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. *Hum.Reprod.Update.* 2006; 12:209–232. [PubMed: 16280356]
127. Hunt JS, Orr HT. HLA and maternal-fetal recognition. *FASEB J.* 1992; 6:2344–2348. [PubMed: 1544544]
128. Ober C, van, d V. Immunogenetics of reproduction: an overview. *Curr.Top.Microbiol.Immunol.* 1997; 222:1–23. [PubMed: 9257483]
129. Ober C. HLA and pregnancy: the paradox of the fetal allograft. *Am J.Hum.Genet.* 1998; 62:1–5. [PubMed: 9443885]
130. Moreau P, Paul P, Rouas-Freiss N, Kirszenbaum M, Dausset J, Carosella ED. Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft. *Am J Reprod.Immunol.* 1998; 40:136–144. [PubMed: 9764357]
131. Rouas-Freiss N, Khalil-Daher I, Marchal-Bras GR, Menier C, Dausset J, Carosella ED. Role of HLA-G in maternal-fetal immune tolerance. *Transplant.Proc.* 1999; 31:724–725. [PubMed: 10083309]
132. Hunt JS. Stranger in a strange land. *Immunol.Rev.* 2006; 213:36–47. [PubMed: 16972895]
133. Hunt JS, Langat DK, McIntire RH, Morales PJ. The role of HLA-G in human pregnancy. *Reprod.Biol.Endocrinol.* 2006; 4(Suppl 1):S10. [PubMed: 17118165]
134. Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. *Science.* 1996; 274:792–795. [PubMed: 8864122]
135. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytotoxicity. *Proc.Natl.Acad.Sci.U.S.A.* 1997; 94:11520–11525. [PubMed: 9326642]
136. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? *Proc.Natl.Acad.Sci.U.S.A.* 1997; 94:5249–5254. [PubMed: 9144223]
137. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, Choppin J, Dausset J, Carosella ED, Kirszenbaum M, Guillet J. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. *Transplant.Proc.* 2001; 33:2355–2359. [PubMed: 11377558]
138. Riteau B, Menier C, Khalil-Daher I, Sedlik C, Dausset J, Rouas-Freiss N, Carosella ED. HLA-G inhibits the allogeneic proliferative response. *J Reprod.Immunol.* 1999; 43:203–211. [PubMed: 10479056]
139. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. *Proc.Natl.Acad.Sci.U.S.A.* 2001; 98:12150–12155. [PubMed: 11572934]
140. LeMaout J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. *Proc.Natl.Acad.Sci.U.S.A.* 2004; 101:7064–7069. [PubMed: 15103024]
141. Le Rond S, Azema C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED, Rouas-Freiss N. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. *J Immunol.* 2006; 176:3266–3276. [PubMed: 16493088]
142. Fournel S, guerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A, Le BP. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. *J.Immunol.* 2000; 164:6100–6104. [PubMed: 10843658]
143. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. *Eur.J.Immunol.* 2003; 33:125–134. [PubMed: 12594841]
144. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, Wiendl H. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. *Blood.* 2007; 110:568–577. [PubMed: 17371944]
145. Ntrivalas EI, Kwak-Kim JY, Gilman-Sachs A, Chung-Bang H, Ng SC, Beaman KD, Mantouvalos HP, Beer AE. Status of peripheral blood natural killer cells in women with recurrent spontaneous

- abortions and infertility of unknown aetiology. *Hum.Reprod.* 2001; 16:855–861. [PubMed: 11331628]
146. Coulam CB, Roussev RG. Increasing circulating T-cell activation markers are linked to subsequent implantation failure after transfer of in vitro fertilized embryos. *Am.J.Reprod.Immunol.* 2003; 50:340–345. [PubMed: 14672338]
 147. Petroff MG, Sedlmayr P, Azzola D, Hunt JS. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. *J.Reprod.Immunol.* 2002; 56:3–17. [PubMed: 12106880]
 148. Hunt JS, Jadhav L, Chu W, Geraghty DE, Ober C. Soluble HLA-G circulates in maternal blood during pregnancy. *Am J.Obstet.Gynecol.* 2000; 183:682–688. [PubMed: 10992193]
 149. Athanassakis I, Pafllis M, Ranella A, Vassiliadis S. Detection of soluble HLA-G levels in maternal serum can be predictive for a successful pregnancy. *Transplant.Proc.* 1999; 31:1834–1837. [PubMed: 10371966]
 150. Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. *Tissue Antigens.* 2006; 67:111–116. [PubMed: 16441481]
 151. Balasch J, Jove I, Martorell J, Gaye A, Vanrell JA. Histocompatibility in in vitro fertilization couples. *Fertil.Steril.* 1993; 59:456–458. [PubMed: 8425649]
 152. Ober C, Aldrich C, Rosinsky B, Robertson A, Walker MA, Willadsen S, Verp MS, Geraghty DE, Hunt JS. HLA-G1 protein expression is not essential for fetal survival. *Placenta.* 1998; 19:127–132. [PubMed: 9548178]
 153. Pfeiffer KA, Rebmann V, Passler M, van, d V, van, d V, Krebs D, Grosse-Wilde H. Soluble HLA levels in early pregnancy after in vitro fertilization. *Hum.Immunol.* 2000; 61:559–564. [PubMed: 10825584]
 154. Aldrich CL, Stephenson MD, Karrison T, Odem RR, Branch DW, Scott JR, Schreiber JR, Ober C. HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. *Mol.Hum.Reprod.* 2001; 7:1167–1172. [PubMed: 11719594]
 155. Pfeiffer KA, Fimmers R, Engels G, van, d V, van, d V. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. *Mol.Hum.Reprod.* 2001; 7:373–378. [PubMed: 11279300]
 156. Hviid TV, Hylenius S, Hoegh AM, Kruse C, Christiansen OB. HLA-G polymorphisms in couples with recurrent spontaneous abortions. *Tissue Antigens.* 2002; 60:122–132. [PubMed: 12392506]
 157. Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B, Bencini E, Menicucci A, Baricordi OR. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. *Eur.J Immunol.* 2002; 32:311–315. [PubMed: 11807769]
 158. Ober C, Aldrich CL, Chervoneva I, Billstrand C, Rahimov F, Gray HL, Hyslop T. Variation in the HLA-G promoter region influences miscarriage rates. *Am J Hum.Genet.* 2003; 72:1425–1435. [PubMed: 12721954]
 159. Sher G, Keskindepe L, Nouriani M, Roussev R, Batzofin J. Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of 'embryo competency' and IVF outcome. *Reprod.Biomed.Online.* 2004; 9:74–78. [PubMed: 15257824]
 160. Abbas A, Tripathi P, Naik S, Agrawal S. Analysis of human leukocyte antigen (HLA)-G polymorphism in normal women and in women with recurrent spontaneous abortions. *Eur.J Immunogenet.* 2004; 31:275–278. [PubMed: 15548266]
 161. Yao YQ, Barlow DH, Sargent IL. Differential expression of alternatively spliced transcripts of HLA-G in human preimplantation embryos and inner cell masses. *J.Immunol.* 2005; 175:8379–8385. [PubMed: 16339579]
 162. Noci I, Fuzzi B, Rizzo R, Melchiorri L, Criscuoli L, Dabizzi S, Biagiotti R, Pellegrini S, Menicucci A, Baricordi OR. Embryonic soluble HLA-G as a marker of developmental potential in embryos. *Hum.Reprod.* 2005; 20:138–146. [PubMed: 15498780]
 163. Sher G, Keskindepe L, Batzofin J, Fisch J, Acacio B, Ahlering P, Ginsburg M. Influence of early ICSI-derived embryo sHLA-G expression on pregnancy and implantation rates: a prospective study. *Hum.Reprod.* 2005; 20:1359–1363. [PubMed: 15746200]
 164. Sher G, Keskindepe L, Fisch JD, Acacio BA, Ahlering P, Batzofin J, Ginsburg M. Soluble human leukocyte antigen G expression in phase I culture media at 46 hours after fertilization predicts

- pregnancy and implantation from day 3 embryo transfer. *Fertil.Steril.* 2005; 83:1410–1413. [PubMed: 15866577]
165. Bhalla A, Stone PR, Liddell HS, Zanderigo A, Chamley LW. Comparison of the expression of human leukocyte antigen (HLA)-G and HLA-E in women with normal pregnancy and those with recurrent miscarriage. *Reproduction.* 2006; 131:583–589. [PubMed: 16514201]
 166. Ober C, Billstrand C, Kuldane S, Tan Z. The miscarriage-associated HLA-G - 725G allele influences transcription rates in JEG-3 cells. *Hum.Reprod.* 2006; 21:1743–1748. [PubMed: 16501035]
 167. Rebmann V, Switala M, Eue I, Schwahn E, Merzenich M, Grosse-Wilde H. Rapid evaluation of soluble HLA-G levels in supernatants of in vitro fertilized embryos. *Hum.Immunol.* 2007; 68:251–258. [PubMed: 17400060]
 168. Goldman-Wohl DS, Ariel I, Greenfield C, Hochner-Celnikier D, Cross J, Fisher S, Yagel S. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. *Mol.Hum.Reprod.* 2000; 6:88–95. [PubMed: 10611266]
 169. Le Bouteiller P, Pizzato N, Barakonyi A, Solier C. HLA-G, pre-eclampsia, immunity and vascular events. *J Reprod.Immunol.* 2003; 59:219–234. [PubMed: 12896824]
 170. Hara N, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody “87G” and anti-cytokeratin antibody “CAM5.2”. *Am J Reprod.Immunol.* 1996; 36:349–358. [PubMed: 8985510]
 171. Yie SM, Li LH, Li YM, Librach C. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. *Am J Obstet.Gynecol.* 2004; 191:525–529. [PubMed: 15343231]
 172. Hylenius S, Andersen AM, Melbye M, Hviid TV. Association between HLA-G genotype and risk of pre-eclampsia: a case-control study using family triads. *Mol.Hum.Reprod.* 2004; 10:237–246. [PubMed: 14985477]
 173. Yie SM, Taylor RN, Librach C. Low plasma HLA-G protein concentrations in early gestation indicate the development of preeclampsia later in pregnancy. *Am.J.Obstet.Gynecol.* 2005; 193:204–208. [PubMed: 16021080]
 174. Datema G, van Meir CA, Kanhai HH, van den Elsen PJ. Pre-term birth and severe pre-eclampsia are not associated with altered expression of HLA on human trophoblasts. *Am J Reprod.Immunol.* 2003; 49:193–201. [PubMed: 12852493]
 175. Hviid TV. HLA-G genotype is associated with fetoplacental growth. *Hum.Immunol.* 2004; 65:586–593. [PubMed: 15219378]
 176. Aldrich C, Verp MS, Walker MA, Ober C. A null mutation in HLA-G is not associated with preeclampsia or intrauterine growth retardation. *J.Reprod.Immunol.* 2000; 47:41–48. [PubMed: 10779589]
 177. Emmer PM, Steegers EA, van Lierop MJ, Steegers-Theunissen RP, Loke YW, Joosten I. Amniotic fluid soluble human leukocyte antigen G is markedly decreased in offspring with neural tube defects. *Early Hum.Dev.* 2002; 66:101–105. [PubMed: 11872314]
 178. Houlihan JM, Biro PA, Harper HM, Jenkinson HJ, Holmes CH. The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. *J Immunol.* 1995; 154:5665–5674. [PubMed: 7751618]
 179. Mazzucchelli I, Avanzini MA, Ciardelli L, Pagani S, Greco R, Belloni C, Castellazzi A, Marconi M, Rondini G, Polatti F. Human amniotic fluid cells are able to produce IL-6 and IL-8. *Am J Reprod.Immunol.* 2004; 51:198–203. [PubMed: 15209388]
 180. Yan WH, Lin A, Chen XJ, Dai MZ, Xu HH, Chen BG, Gan LH, Shi WW. Immunological aspects of human amniotic fluid cells: implication for normal pregnancy. *Cell Biol.Int.* 2008; 32:93–99. [PubMed: 17920941]
 181. Hamai Y, Fujii T, Miki A, Geraghty DE, Harada I, Takai Y, Kozuma S, Tsutsumi O, Taketani Y. Quantitative assessment of human leukocyte antigen-G protein in amniotic fluid by a double-determinant enzyme-linked immunosorbent assay using anti-human leukocyte antigen-G-specific antibody ‘87G’. *Am.J.Reprod.Immunol.* 1999; 41:293–295. [PubMed: 10374707]

182. Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, Fabiani JN, Dausset J, Carosella ED, Carpentier A. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. *Circulation*. 2002; 105:1949–1954. [PubMed: 11997282]
183. Amiot L, Onno M, Drenou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. *Hum.Immunol*. 1998; 59:524–528. [PubMed: 9712358]
184. Onno M, Pangault C, Le FG, Guilloux V, Andre P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. *J Immunol*. 2000; 164:6426–6434. [PubMed: 10843698]
185. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. *Trends Immunol*. 2001; 22:553–555. [PubMed: 11574278]
186. Torres MI, Lopez Casado MA, Rios A. New aspects in celiac disease. *World J Gastroenterol*. 2007; 13:1156–1161. [PubMed: 17451193]
187. Torres MI, Le DM, Lorite P, Rios A, Gassull MA, Gil A, Maldonado J, Dausset J, Carosella ED. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. *Int.Immunol*. 2004; 16:579–583. [PubMed: 15039388]
188. Rizzo R, Melchiorri L, Simone L, Stignani M, Marzola A, Gullini S, Baricordi OR. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn's disease: a noninvasive diagnostic tool? *Inflamm.Bowel.Dis*. 2008; 14:100–105. [PubMed: 17886287]
189. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. *J Neuroimmunol*. 2005; 159:155–164. [PubMed: 15652415]
190. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Paolino E, Tola MR, Granieri E, Baricordi OR. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. *Mult.Scler*. 2006; 12:2–12. [PubMed: 16459714]
191. Airas L, Nikula T, Huang YH, Lahesmaa R, Wiendl H. Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. *J Neuroimmunol*. 2007; 187:205–211. [PubMed: 17561269]
192. Rizzo R, Mapp CE, Melchiorri L, Maestrelli P, Visentin A, Ferretti S, Bononi I, Miotto D, Baricordi OR. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. *J Allergy Clin.Immunol*. 2005; 115:508–513. [PubMed: 15753897]
193. Nicolae D, Cox NJ, Lester LA, Schneider D, Tan Z, Billstrand C, Kuldane S, Donfack J, Kogut P, Patel NM, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. *Am J Hum.Genet*. 2005; 76:349–357. [PubMed: 15611928]
194. Ober C. HLA-G: an asthma gene on chromosome 6p. *Immunol.Allergy Clin.North Am*. 2005; 25:669–679. [PubMed: 16257632]
195. Verbruggen LA, Rebmann V, Demanet C, De CS, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. *Hum.Immunol*. 2006; 67:561–567. [PubMed: 16916651]
196. Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. *Ann.Neurol*. 2000; 48:679–684. [PubMed: 11026456]
197. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmuller H, Hohlfeld R, Melms A, Weller M. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. *Brain*. 2003; 126:176–185. [PubMed: 12477705]
198. McIntire RH, Morales PJ, Petroff MG, Colonna M, Hunt JS. Recombinant HLA-G5 and -G6 drive U937 myelomonocytic cell production of TGF-beta1. *J Leukoc.Biol*. 2004; 76:1220–1228. [PubMed: 15459235]

199. McIntire RH, Hunt JS. Antigen presenting cells and HLA-G--a review. *Placenta*. 2005; 26(Suppl A):S104–S109. [PubMed: 15837058]
200. Moreau P, drian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. *Int.Immunol*. 1999; 11:803–811. [PubMed: 10330285]
201. Gotsch F, Romero R, Kusanovic JP, Erez O, Espinoza J, Kim CJ, Vaisbuch E, Than NG, Mazaki-Tovi S, Chaiworapongsa T, et al. The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: a role for interleukin-10. *J Matern.Fetal Neonatal Med*. 2008; 21:529–547. [PubMed: 18609361]
202. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. *Immunology*. 2000; 101:191–200. [PubMed: 11012772]
203. Kanai T, Fujii T, Unno N, Yamashita T, Hyodo H, Miki A, Hamai Y, Kozuma S, Taketani Y. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. *Am J Reprod.Immunol*. 2001; 45:94–99. [PubMed: 11216880]

Figure 1. Amniotic fluid concentration of sHLA-G in normal pregnancies at mid-trimester and in those at term not in labor

No significant differences were observed in the median sHLA-G concentration in amniotic fluid between women in the mid-trimester and those with a normal pregnancy at term not in labor [60.7 U/mL, interquartile range (IQR) 28.6–96 vs. 47.6 U/mL, IQR 33.5–69, respectively; $p=0.5$].

Figure 2. Amniotic fluid concentration of sHLA-G in normal pregnancies with and without spontaneous labor at term

Women with spontaneous labor at term had a significantly lower median amniotic fluid sHLA-G concentration than those without labor (36.2 U/mL, IQR 22.9–57.8 vs. 47.6 U/mL, IQR 33.5–69, respectively; $p=0.02$).

Figure 3. Amniotic fluid concentration of sHLA-G among patients with spontaneous preterm labor and intact membranes (PTL)

Patients with spontaneous preterm labor with intact membranes with intra-amniotic infection/inflammation (IAI) had a significantly higher median amniotic fluid concentration of sHLA-G than those who delivered preterm without IAI (PTL with IAI: 88.4 U/mL, IQR 43.5–142.9 vs. PTL without IAI: 46.5 U/mL, IQR 26.9–73.9; $p < 0.001$) and those with spontaneous preterm labor with intact membranes who delivered at term (PTL with IAI: 88.4 U/mL, IQR 43.5–142.9 vs. PTL delivered at term: 50.4 U/mL, IQR 29.8–85.9; $p < 0.001$). There were no differences in the median amniotic fluid sHLA-G concentration between patients with spontaneous preterm labor without IAI who delivered preterm and those who delivered at term.

Figure 4. Amniotic fluid concentration of sHLA-G in patients with preterm prelabor rupture of the membranes (preterm PROM)

Patients with preterm PROM with IAI had a significantly higher median amniotic fluid sHLA-G concentration than those with preterm PROM without IAI (76.7 U/mL, IQR 39.7–135.4 vs. 46.6 U/mL, IQR 25.8–94.9, respectively; $p=0.004$).

Figure 5. Amniotic fluid concentration of sHLA-G in patients with spontaneous preterm labor with and without histologic chorioamnionitis who delivered within 72 hours from amniocentesis Patients with histologic chorioamnionitis and/or funisitis had a significantly higher median sHLA-G concentration in amniotic fluid than those without histologic inflammation (122.7 U/mL, IQR 79–190.1 vs. 47.7 U/mL, IQR 28.3–83.7, respectively; $p < 0.001$).

Table 1

Demographic and clinical characteristics of patients in the mid-trimester and those at term with and without spontaneous labor

	Mid-trimester (n=55)	p ^a	Term No labor (n=50)	Term In labor (n=50)	p ^b
Maternal age (years)	36 (35–38)	<0.01	27 (21–32)	22 (19–27)	<0.01
Gestational age at amniocentesis (weeks)	16 (16–17)	<0.01	39 (38–39)	38.6 (37.9–39.4)	NS
Gestational age at delivery (weeks)	39 (38–40)	NS	39 (38–39)	38.5 (37.9–39.4)	NS
Birthweight (grams)	3,344 (3,113–3,604)	NS	3,260 (3,080–3,630)	3,375 (3,093–3,563)	NS

Values are expressed as percentage (number) or median (interquartile range).

NS: not significant.

p^a: comparison between patients in the mid-trimester and those at term not in labor

p^b: comparison between patients at term not in labor and those at term in labor

Table II
Demographic and clinical characteristics of patients presenting with spontaneous preterm labor with intact membranes

	PTL without IAI	Term delivery (n=153)	p	PTL without IAI	Preterm delivery (n=108)	p ^a	PTL with IAI	Preterm delivery (n=84)	p ^b
Maternal age (yrs)	22 (19–30)		NS	22 (19–30)		NS	23 (20–28)		NS
Smoking	18.4 (28/152)		NS	10.4 (11/106)		0.001	30 (24/80)		0.04
BMI (Kg/m ²)	22.7 (20.1–25.5)		NS	22.3 (20.1–25.2)		<0.01	25 (21.8–30)		<0.01
GA at amniocentesis (wks)	31.9 (29.4–33.3)		NS	31.9 (29.8–33.1)		<0.01	28.8 (25.1–33)		<0.01
GA at delivery (wks)	38.7 (38–39.7)		<0.01	34.6 (33.3–35.6)		<0.01	29.8 (25.6–33.3)		<0.01
Birthweight (grs)	3,170 (2,900–3,515)		<0.01	2,330 (1,940–2,678)		<0.01	1,310 (735–2,118)		<0.01

Values expressed as percentage (number) or median (interquartile range)

PTL: preterm labor; GA: gestational age; BMI: body mass index; IAI: intra-amniotic infection/inflammation NS: not significant p^a: comparison between PTL who delivered preterm without IAI and PTL with IAI; p^b: comparison between PTL who delivered at term without IAI and PTL with IAI

Table III

Demographic and clinical characteristics of patients presenting with preterm prelabor rupture of membranes

	Preterm PROM without IAI (n=44)	Preterm PROM with IAI (n=46)	p
Maternal age (yrs)	24.5 (20–32.8)	30 (23.5–37.5)	0.008
Smoking	18.2 (8/44)	17.8 (8/45)	NS
BMI (Kg/m ²)	24.5 (21.5–28.8)	25.3 (23.5–27.7)	NS
GA at amniocentesis (wks)	32.6 (29.4–33.8)	30.5 (27.9–32.4)	0.02
GA at delivery (wks)	33.2 (31.4–34.4)	30.8 (28.7–33.1)	<0.001
Birthweight (grs)	2,020 (1,678–2,323)	1,645 (1,385–2,120)	0.02

Values expressed as percentage (number) or median (interquartile range)

PROM: prelabor rupture of membranes; GA: gestational age; BMI: body mass index; IAI: intra-amniotic infection/inflammation NS: not significant.